Alan Tan· @alantanmd · X·· 23 hours agoScore70
Body
PROTEUS substudy at #ESMO26 presented by Alberto Briganti 🇪🇸
Perioperative apalutamide + ADT vs RP + PLND alone in HR localized/LA prostate cancer (N=408, 1:3)
▪️ EFS HR 0.38 (0.26–0.55), p<0.0001
▪️ 36-mo EFS 63% vs 41%; SOC median EFS only 19.1 mo
▪️ Benefit held after T recovery
@neerajaiims @DrChoueiri @DrRanaMcKay @tompowles1 #ProstateCancer
41 views · 0 likes · 0 reposts · 2 replies
Replies in this thread
- Alan Tan@alantanmd
More PROTEUS results: events, MFS and time to subsequent therapy #ESMO26
- Alan Tan@alantanmd
▪️ MFS by BICR HR 0.49 (0.26–0.90) ▪️ Fewer PSMA-PET LRR/DM events ▪️ Time to next therapy 46.0 vs 12.3 mo, HR 0.29 Big question for #GUonc: should perioperative ARPI + ADT become the new standard over surgery + selective adjuvant? 🤔
Source: Alan Tan · x.com